Commerzbank Aktiengesellschaft’s Gilead Sciences GILD Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-61,900	Closed	-$404K	–	910
2019 Q2	$404K	Buy	+61,900	New	+$4.07M	﹤0.01%	784
2018 Q1	–	Sell	-198,600	Closed	-$133K	–	976
2017 Q4	$133K	Buy	+198,600	New	+$15.1M	﹤0.01%	850
2016 Q1	–	Sell	-50,000	Closed	-$5.06M	–	1080
2015 Q4	$5.06M	Hold	50,000	–	–	0.04%	304
2015 Q3	$4.91M	Hold	50,000	–	–	0.04%	279
2015 Q2	$5.85M	Buy	+50,000	New	+$5.46M	0.03%	324
2015 Q1	–	Sell	-60,000	Closed	-$5.66M	–	1179
2014 Q4	$5.66M	Hold	60,000	–	–	0.04%	384
2014 Q3	$6.39M	Hold	60,000	–	–	0.03%	424
2014 Q2	$4.97M	Hold	60,000	–	–	0.03%	467
2014 Q1	$4.25M	Buy	60,000 +20,800	+53%	+$1.63M	0.02%	504
2013 Q4	$3.16M	Buy	39,200 +19,200	+96%	+$1.34M	0.02%	614
2013 Q3	$1.26M	Buy	20,000 +15,800	+376%	+$944K	0.01%	808
2013 Q2	$215K	Buy	+4,200	New	+$219K	﹤0.01%	1350

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Commerzbank Aktiengesellschaft's GILD Position: Q2 2026 in Review

Commerzbank Aktiengesellschaft reduced its Gilead Sciences (GILD) stake by 24% in Q2 2026, selling an estimated $1.74M and leaving 41,571 shares worth $5.25M. The position accounts for 0.1% of the portfolio, ranked #91.

Commerzbank Aktiengesellschaft first reported a position in GILD in Q2 2013 and has held it in 40 quarters since. The position peaked at $173M in Q3 2014. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Commerzbank Aktiengesellschaft held 41,571 shares of Gilead Sciences worth $5.25M as of Q2 2026.
Commerzbank Aktiengesellschaft sold 13,185 Gilead Sciences shares in Q2 2026, an estimated $1.74M.
Gilead Sciences made up 0.1% of Commerzbank Aktiengesellschaft's portfolio in Q2 2026, its #91 holding.
Commerzbank Aktiengesellschaft first reported a position in Gilead Sciences in Q2 2013 and has held it in 40 quarters since.
Commerzbank Aktiengesellschaft's Gilead Sciences position peaked at $173M in Q3 2014.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q2 2026, filed 7 Aug 2026.